The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
Abstract
OBJECTIVES: Infliximab (IFX) is successfully used in the treatment of inflammatory bowel diseases but some patients generate antibodies to IFX (ATI) jeopardizing the pharmacokinetics of the drug. Little is known about the factors influencing ATI formation and whether or not this immune reaction is permanent. Our aim was to investigate the kinetics of ATI formation and drug levels in relation to inflammatory markers and the clinical evolution of the patients. METHODS: IFX trough and ATI levels were measured retrospectively in 1,232 consecutive serum samples of 90 (64 Crohn's disease and 26 ulcerative colitis) patients, 57 with previously detected and 33 without antibodies with a new homogenous mobility shift assay. RESULTS: Testing with new assay confirmed ATI in 53/90 patients (59%) and 37/90 patients (41%) were ATI negative. In 15/53 patients (28%), ATI disappeared over time whereas in 38/53 patients (72%) ATI persisted. The 26/38 (68%) patients with sustained ATI needed to discontinue IFX treatment compared with 2/15 (13%) patients with transient ATI (relative risk 5.1; 95% confidence interval 1.4-19.0; P=0.0005). An IFX trough level at week 14<2.2 μg/ml predicted IFX discontinuation due to persistent loss of response (LOR) or hypersensitivity reactions with 74% specificity and 82% sensitivity (likelihood ratio 3.1; P=0.0026). CONCLUSIONS: ATI may be transient and do not always lead to a worse clinical outcome. Sustained high levels of ATI, however, lead to permanent LOR. Patients with low IFX trough levels at week 14 are at risk for ATI formation and IFX discontinuation. Therefore, we recommend to measure IFX trough levels at week 14 and at time of LOR. When undetectable or low, ATI should be determined and if positive followed up on consecutive time points to rule out sustained ATI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationInfliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Self-citationInfliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Self-citationInfluence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Self-citationColombel, J. F., Rutgeerts, P., Reinisch, W., Esser, D., Wang, Y., Lang, Y., Marano, C. W., Strauss, R., Oddens, B. J., Feagan, B. G., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.054 · Cited by 919
Self-citationBartelds, G. M. (2011) · JAMA · doi:10.1001/jama.2011.406 · Cited by 782
Hanauer, S. B., Wagner, C. L., BALA, M. M., Mayer, L., Travers, S., Diamond, R. H., Olson, A. D., Bao, W., & Rutgeerts, P. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00238-1 · Cited by 636
Self-citationMaser, E. A., Villela, R., Silverberg, M. S., & Greenberg, G. R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.06.025 · Cited by 613
Vermeire, S., Noman, M., Van Assche, G., Baert, F., D’Haens, G., & Rutgeerts, P. (2007) · Gut · doi:10.1136/gut.2006.099978 · Cited by 602
Self-citationSeow, C. H., Newman, A., Irwin, S. P., Steinhart, A. H., Silverberg, M. S., & Greenberg, G. R. (2010) · Gut · doi:10.1136/gut.2009.183095 · Cited by 536
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease
Ruemmele, F. M., Veres, G., Kolho, K. L., Griffiths, A., Levine, A., Escher, J. C., Amil Dias, J., Barabino, A., Braegger, C. P., Bronsky, J., et al. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.04.005 · Cited by 1,083
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Vande Casteele, N., Ferrante, M., Van Assche, G., Ballet, V., Compernolle, G., Van Steen, K., Simoens, S., Rutgeerts, P., Gils, A., & Vermeire, S. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.031 · Cited by 886
Self-citationLoss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Roda, G., Jharap, B., Neeraj, N., & Colombel, J.-F. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.63 · Cited by 723
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
Nguyen, G. C., Seow, C. H., Maxwell, C., Huang, V., Leung, Y., Jones, J., Leontiadis, G. I., Tse, F., Mahadevan, U., van der Woude, C. J., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.003 · Cited by 473
Bressler, B., Marshall, J. K., Bernstein, C. N., Bitton, A., Jones, J., Leontiadis, G. I., Panaccione, R., Steinhart, A. H., Tse, F., Feagan, B., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.001 · Cited by 413
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
Strand, V., Balsa, A., Al-Saleh, J., Barile-Fabris, L., Horiuchi, T., Takeuchi, T., Lula, S., Hawes, C., Kola, B., & Marshall, L. (2017) · BioDrugs · doi:10.1007/s40259-017-0231-8 · Cited by 353
Adedokun, O. J., Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Xu, Z., Marano, C. W., Johanns, J., Zhou, H., Davis, H. M., Cornillie, F., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.035 · Cited by 341
Self-citationFeagan, B. G., McDonald, J. W. D., Panaccione, R., Enns, R. A., Bernstein, C. N., Ponich, T. P., Bourdages, R., MacIntosh, D. G., Dallaire, C., Cohen, A., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.024 · Cited by 331
Yanai, H., Lichtenstein, L., Assa, A., Mazor, Y., Weiss, B., Levine, A., Ron, Y., Kopylov, U., Bujanover, Y., Rosenbach, Y., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.07.029 · Cited by 316
Ungar, B., Chowers, Y., Yavzori, M., Picard, O., Fudim, E., Har-Noy, O., Kopylov, U., Eliakim, R., Ben-Horin, S., & on behalf of ABIRISK consortium (2014) · Gut · doi:10.1136/gutjnl-2013-305259 · Cited by 309
Vande Casteele, N., Herfarth, H., Katz, J., Falck-Ytter, Y., & Singh, S. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.07.031 · Cited by 295
Self-citationDotan, I., Ron, Y., Yanai, H., Becker, S., Fishman, S., Yahav, L., Ben Yehoyada, M., & Mould, D. R. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000212 · Cited by 291
Vande Casteele, N., Khanna, R., Levesque, B. G., Stitt, L., Zou, G. Y., Singh, S., Lockton, S., Hauenstein, S., Ohrmund, L., Greenberg, G. R., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-307883 · Cited by 289
Self-citationMitrev, N., Vande Casteele, N., Seow, C. H., Andrews, J. M., Connor, S. J., Moore, G. T., Barclay, M., Begun, J., Bryant, R., Chan, W., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14368 · Cited by 282
Self-citationAnti-TNF Therapy in Crohn’s Disease
Adegbola, S. O., Sahnan, K., Warusavitarne, J., Hart, A., & Tozer, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082244 · Cited by 274
Metadata
- Authors
- Vande Casteele, N., Gils, A., Singh, S., Ohrmund, L., Hauenstein, S., Rutgeerts, P., & Vermeire, S.
- Venue
- American Journal of Gastroenterology
- Published
- 2013-06
- Volume
- 108
- Issue
- 6
- Pages
- 962-971
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2087663450
- Cited by
- 346
- References
- 27
- FWCI
- 28.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.